Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 1/2014

01-01-2014 | Stroke (H Adams, Section Editor)

Recent Advances in Moyamoya Disease: Pathophysiology and Treatment

Authors: Annick Kronenburg, Kees P. J. Braun, Albert van der Zwan, Catharina J. M. Klijn

Published in: Current Neurology and Neuroscience Reports | Issue 1/2014

Login to get access

Abstract

Moyamoya disease is a progressive intracranial arteriopathy characterized by bilateral stenosis of the distal portion of the internal carotid artery and the proximal anterior and middle cerebral arteries, resulting in transient ischemic attacks or strokes. The pathogenesis of moyamoya disease remains unresolved, but recent advances have suggested exciting new insights into a genetic contribution as well as into other pathophysiological mechanisms. Treatment that may halt progression of the disease or even reverse the intracranial arteriopathy is yet to be found. There are strong indications that neurosurgical intervention, through direct, indirect, or combined revascularization surgery, can reduce the risk of ischemic stroke and possibly also cognitive dysfunction by improving cerebral perfusion, although randomized clinical trials have not been performed. Many questions regarding the indication for and timing of surgery remain unanswered. In this review, we discuss recent developments in the pathogenesis and treatment of moyamoya disease.
Literature
1.
2.
Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20:288–99.PubMedCrossRef
3.
Kleinloog R, Regli L, Rinkel GJ, Klijn CJ. Regional differences in incidence and patient characteristics of moyamoya disease: a systematic review. J Neurol Neurosurg Psychiatry. 2012;83:531–6.PubMedCrossRef
4.
Cho HJ, Jung YH, Kim YD, et al. The different infarct patterns between adulthood-onset and childhood-onset moyamoya disease. J Neurol Neurosurg Psychiatry. 2011;82:38–40.PubMedCrossRef
5.
Takekawa Y, Umezawa T, Ueno Y, Sawada T, Kobayashi M. Pathological and immunohistochemical findings of an autopsy case of adult moyamoya disease. Neuropathology. 2004;24:236–42.PubMedCrossRef
6.
Hosoda Y, Ikeda E, Hirose S. Histopathological studies on spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease). Clin Neurol Neurosurg. 1997;99 Suppl 2:S203–8.PubMedCrossRef
7.
Kaku Y, Morioka M, Ohmori Y, et al. Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image: is arterial constrictive remodeling a major pathogenesis? Acta Neurochir (Wien). 2012;154:2151–7.CrossRef
8.
Kim JM, Jung KH, Sohn CH, et al. High-resolution MR technique can distinguish moyamoya disease from atherosclerotic occlusion. Neurology. 2013;80:775–6.PubMedCrossRef
9.
Yamashita M, Tanaka K, Matsuo T, et al. Cerebral dissecting aneurysms in patients with moyamoya disease. Report of two cases. J Neurosurg. 1983;58:120–5.PubMedCrossRef
10.
Houkin K, Ito M, Sugiyama T, et al. Review of past research and current concepts on the etiology of moyamoya disease. Neurol Med Chir (Tokyo). 2012;52:267–77.
11.
Jiang T, Perry A, Dacey Jr RG, Zipfel GJ, Derdeyn CP. Intracranial atherosclerotic disease associated with moyamoya collateral formation: histopathological findings. J Neurosurg. 2013;118:1030–4.PubMedCrossRef
12.
Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry. 2008;79:900–4.PubMedCrossRef
13.
Mineharu Y, Takenaka K, Yamakawa H, et al. Inheritance pattern of familial moyamoya disease: autosomal dominant mode and genomic imprinting. J Neurol Neurosurg Psychiatry. 2006;77:1025–9.PubMedCrossRef
14.
Kraemer M, Heinemann FM, Horn PA, et al. Inheritance of moyamoya disease in a Caucasian family. Eur J Neurol. 2012;19:438–42.PubMedCrossRef
15.
Herve D, Touraine P, Verloes A, et al. A hereditary moyamoya syndrome with multisystemic manifestations. Neurology. 2010;75:259–64.PubMedCrossRef
16.
• Munot P, Saunders DE, Milewicz DM, et al. A novel distinctive cerebrovascular phenotype is associated with heterozygous Arg179 ACTA2 mutations. Brain. 2012;135:2506–14. This article describes the distinctive angiographic features of the intracranial vasculopathy associated with ACTA2 mutations.PubMedCrossRef
17.
18.
•• Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011;6:e22542. This study (as well as [19]) has identified RNF213 as the first MMD gene.PubMedCentralPubMedCrossRef
19.
•• Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet. 2011;56:34–40. This study (as well as [18]) has identified RNF213 as the first MMD gene.PubMedCrossRef
20.
21.
Liu W, Hitomi T, Kobayashi H, Harada KH, Koizumi A. Distribution of moyamoya disease susceptibility polymorphism p.R4810K in RNF213 in East and Southeast Asian populations. Neurol Med Chir (Tokyo). 2012;52:299–303.
22.
Miyawaki S, Imai H, Takayanagi S, et al. Identification of a genetic variant common to moyamoya disease and intracranial major artery stenosis/occlusion. Stroke. 2012;43:3371–4.PubMedCrossRef
23.
Hitomi T, Habu T, Kobayashi H, et al. Downregulation of securin by the variant RNF213 R4810K reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients. Biochem Biophys Res Commun. 2013;438(1):13–9.PubMedCrossRef
24.
Miyatake S, Miyake N, Touho H, et al. Homozygous c.14576G > A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012;78:803–10.PubMedCrossRef
25.
Achrol AS, Guzman R, Lee M, Steinberg GK. Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus. 2009;26:E4.PubMedCrossRef
26.
Houkin K, Ito M, Sugiyama T, et al. Review of past research and current concepts on the etiology of moyamoya disease. Neurol Med Chir (Tokyo). 2012;52:267–77.
27.
Kang HS, Kim JH, Phi JH, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010;81:673–8.PubMedCrossRef
28.
29.
Fujimura M, Watanabe M, Narisawa A, Shimizu H, Tominaga T. Increased expression of serum matrix metalloproteinase-9 in patients with moyamoya disease. Surg Neurol. 2009;72:476–80. discussion 480.PubMedCrossRef
30.
Kim JH, Jung JH, Phi JH, et al. Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease. J Neurosci Res. 2010;88:510–8.PubMed
31.
Kang HS, Kim JH, Phi JH, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010;81:673–8.PubMedCrossRef
32.
Jung KH, Chu K, Lee ST, et al. Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J Cereb Blood Flow Metab. 2008;28:1795–803.PubMedCrossRef
33.
Zou D, Zhao J, Zhang D, et al. Enhancement expression of bFGF in Chinese patients with moyamoya disease. Biomed Environ Sci. 2011;24:74–80.PubMed
34.
Koh EJ, Kim HN, Ma TZ, Choi HY, Kwak YG. Comparative analysis of serum proteomes of moyamoya disease and normal controls. J Korean Neurosurg Soc. 2010;48:8–13.PubMedCentralPubMedCrossRef
35.
Araki Y, Yoshikawa K, Okamoto S, et al. Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS. BMC Neurol. 2010;10:112.PubMedCentralPubMedCrossRef
36.
• Lin R, Xie Z, Zhang J, et al. Clinical and immunopathological features of moyamoya disease. PLoS One. 2012;7:e36386. This study reports the immunological results from a large group of MMD patients (n = 65), including the histopathological features of three patients.PubMedCentralPubMedCrossRef
37.
• Sigdel TK, Shoemaker LD, Chen R, et al. Immune response profiling identifies autoantibodies specific to moyamoya patients. Orphanet J Rare Dis. 2013;8:45. This is the first study to provide high-throughput analysis of autoantibodies in MMD.PubMedCentralPubMedCrossRef
38.
Bower RS, Mallory GW, Nwojo M, et al. Moyamoya disease in a primarily white, Midwestern US population: increased prevalence of autoimmune disease. Stroke. 2013;44:1997–9.PubMedCrossRef
39.
Li H, Zhang ZS, Dong ZN, et al. Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease: a case-control study. Stroke. 2011;42:1138–9.PubMedCrossRef
40.
Kim SJ, Heo KG, Shin HY, et al. Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease: a prospective study. Stroke. 2010;41:173–6.PubMedCrossRef
41.
Kraemer M, Berlit P, Diesner F, Khan N. What is the expert's option on antiplatelet therapy in moyamoya disease? Results of a worldwide survey. Eur J Neurol. 2012;19:163–7.PubMedCrossRef
42.
• Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant for Research on Measures for Intractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012;52:245–66. This article extensively reports the evidence-based guidelines for the diagnosis and treatment of MMV.
43.
44.
Ganesan V. Moyamoya: to cut or not to cut is not the only question. A paediatric neurologist's perspective. Dev Med Child Neurol. 2010;52:10–3.PubMedCrossRef
45.
Khan N, Dodd R, Marks MP, et al. Failure of primary percutaneous angioplasty and stenting in the prevention of ischemia in moyamoya angiopathy. Cerebrovasc Dis. 2011;31:147–53.PubMedCrossRef
46.
• Smith ER, Scott RM. Spontaneous occlusion of the circle of Willis in children: pediatric moyamoya summary with proposed evidence-based practice guidelines. A review. J Neurosurg Pediatr. 2012;9:353–60. This article offers practical guidelines with specific evidence-based guidelines for (surgical) treatment.PubMedCrossRef
47.
Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke. 2008;39:2644–91.PubMedCrossRef
48.
Fung LW, Thompson D, Ganesan V. Revascularisation surgery for paediatric moyamoya: a review of the literature. Childs Nerv Syst. 2005;21:358–64.PubMedCrossRef
49.
Gross BA, Du R. The natural history of moyamoya in a North American adult cohort. J Clin Neurosci. 2013;20:44–8.PubMedCrossRef
50.
Kuroda S, Ishikawa T, Houkin K, et al. Incidence and clinical features of disease progression in adult moyamoya disease. Stroke. 2005;36:2148–53.PubMedCrossRef
51.
Abla AA, Gandhoke G, Clark JC, et al. Surgical outcomes for moyamoya angiopathy at Barrow Neurological Institute with comparison of adult indirect EDAS bypass, adult direct STA-MCA bypass and pediatric bypass: 154 revascularization surgeries in 140 affected hemispheres. Neurosurgery. 2013;73(3):430–9.PubMedCrossRef
52.
Guzman R, Lee M, Achrol A, et al. Clinical outcome after 450 revascularization procedures for moyamoya disease. Clinical article. J Neurosurg. 2009;111:927–35.PubMedCrossRef
53.
Bao XY, Duan L, Li DS, et al. Clinical features, surgical treatment and long-term outcome in adult patients with moyamoya disease in China. Cerebrovasc Dis. 2012;34:305–13.PubMedCrossRef
54.
Dusick JR, Gonzalez NR, Martin NA. Clinical and angiographic outcomes from indirect revascularization surgery for moyamoya disease in adults and children: a review of 63 procedures. Neurosurgery. 2011;68:34–43. discussion 43.PubMedCrossRef
55.
Duan L, Bao XY, Yang WZ, et al. Moyamoya disease in China: its clinical features and outcomes. Stroke. 2012;43:56–60.PubMedCrossRef
56.
Mukawa M, Nariai T, Matsushima Y, et al. Long-term follow-up of surgically treated juvenile patients with moyamoya disease. J Neurosurg Pediatr. 2012;10:451–6.PubMedCrossRef
57.
58.
Okada Y, Kawamata T, Kawashima A, et al. The efficacy of superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease complaining of severe headache. J Neurosurg. 2012;116:672–9.PubMedCrossRef
59.
60.
Miyamoto S, Japan Adult Moyamoya Trial Group. Study design for a prospective randomized trial of extracranial-intracranial bypass surgery for adults with moyamoya disease and hemorrhagic onset—the Japan Adult Moyamoya Trial Group. Neurol Med Chir (Tokyo). 2004;44:218–9.CrossRef
61.
Liu X, Zhang D, Shuo W, et al. Long term outcome after conservative and surgical treatment of haemorrhagic moyamoya disease. J Neurol Neurosurg Psychiatry. 2013;84:258–65.PubMedCrossRef
62.
Ryan RW, Chowdhary A, Britz GW. Hemorrhage and risk of further hemorrhagic strokes following cerebral revascularization in moyamoya disease: a review of the literature. Surg Neurol Int. 2012;3:72.PubMedCentralPubMedCrossRef
63.
Lee JY, Phi JH, Wang KC, et al. Neurocognitive profiles of children with moyamoya disease before and after surgical intervention. Cerebrovasc Dis. 2011;31:230–7.PubMedCrossRef
64.
Karzmark P, Zeifert PD, Bell-Stephens TE, Steinberg GK, Dorfman LJ. Neurocognitive impairment in adults with moyamoya disease without stroke. Neurosurgery. 2012;70:634–8.PubMedCrossRef
65.
Weinberg DG, Rahme RJ, Aoun SG, Batjer HH, Bendok BR. Moyamoya disease: functional and neurocognitive outcomes in the pediatric and adult populations. Neurosurg Focus. 2011;30:E21.PubMedCrossRef
66.
67.
Calviere L, Ssi Yan Kai G, Catalaa I, et al. Executive dysfunction in adults with moyamoya disease is associated with increased diffusion in frontal white matter. J Neurol Neurosurg Psychiatry. 2012;83:591–3.PubMedCrossRef
68.
Khan N, Schuknecht B, Boltshauser E, et al. Moyamoya disease and moyamoya syndrome: experience in Europe; choice of revascularisation procedures. Acta Neurochir (Wien). 2003;145:1061–71. discussion 1071.CrossRef
69.
70.
Han JS, Mikulis DJ, Mardimae A, et al. Measurement of cerebrovascular reactivity in pediatric patients with cerebral vasculopathy using blood oxygen level-dependent MRI. Stroke. 2011;42:1261–9.PubMedCrossRef
71.
Zaharchuk G, Do HM, Marks MP, et al. Arterial spin-labeling MRI can identify the presence and intensity of collateral perfusion in patients with moyamoya disease. Stroke. 2011;42:2485–91.PubMedCentralPubMedCrossRef
72.
Noguchi T, Kawashima M, Irie H, et al. Arterial spin-labeling MR imaging in moyamoya disease compared with SPECT imaging. Eur J Radiol. 2011;80:e557–62.PubMedCrossRef
73.
Rim NJ, Kim HS, Shin YS. Kim SY Which CT perfusion parameter best reflects cerebrovascular reserve?: correlation of acetazolamide-challenged CT perfusion with single-photon emission CT in moyamoya patients. AJNR Am J Neuroradiol. 2008;29:1658–63.PubMedCrossRef
74.
Zhang J, Wang J, Geng D, et al. Whole-brain CT perfusion and CT angiography assessment of moyamoya disease before and after surgical revascularization: preliminary study with 256-slice CT. PLoS One. 2013;8:e57595.PubMedCentralPubMedCrossRef
75.
Guzman R, Steinberg GK. Direct bypass techniques for the treatment of pediatric moyamoya disease. Neurosurg Clin N Am. 2010;21:565–73.PubMedCrossRef
76.
Khan N, Yonekawa Y. Moyamoya angiopathy in Europe: the beginnings in Zürich, practical lessons learned, increasing awareness and future perspectives. Acta Neurochir Suppl. 2008;103:127–30.PubMedCrossRef
77.
Patel NN, Mangano FT, Klimo Jr P. Indirect revascularization techniques for treating moyamoya disease. Neurosurg Clin N Am. 2010;21:553–63.PubMedCrossRef
78.
79.
Oliveira RS, Amato MC, Simao GN, et al. Effect of multiple cranial burr hole surgery on prevention of recurrent ischemic attacks in children with moyamoya disease. Neuropediatrics. 2009;40:260–4.PubMedCrossRef
80.
Kim DS, Huh PW, Kim HS, et al. Surgical treatment of moyamoya disease in adults: combined direct and indirect vs. indirect bypass surgery. Neurol Med Chir (Tokyo). 2012;52:333–8.
81.
Hayashi T, Shirane R, Tominaga T. Additional surgery for postoperative ischemic symptoms in patients with moyamoya disease: the effectiveness of occipital artery-posterior cerebral artery bypass with an indirect procedure: technical case report. Neurosurgery. 2009;64:E195–6. discussion E196.PubMedCrossRef
82.
Horiuchi T, Kusano Y, Asanuma M, Hongo K. Posterior auricular artery-middle cerebral artery bypass for additional surgery of moyamoya disease. Acta Neurochir (Wien). 2012;154:455–6.CrossRef
83.
Kawashima A, Kawamata T, Yamaguchi K, Hori T, Okada Y. Successful superficial temporal artery-anterior cerebral artery direct bypass using a long graft for moyamoya disease: technical note. Neurosurgery. 2010;67:ons145–9. discussion ons149.PubMedCrossRef
84.
Kuroda S, Houkin K, Ishikawa T, Nakayama N, Iwasaki Y. Novel bypass surgery for moyamoya disease using pericranial flap: its impacts on cerebral hemodynamics and long-term outcome. Neurosurgery. 2010;66:1093–101. discussion 1101.PubMedCrossRef
85.
McLaughlin N, Martin NA. Meningeal management for optimal revascularization from middle meningeal artery. J Neurosurg. 2013;118:104–8.PubMedCrossRef
86.
Kronenburg A, Esposito G, Fierstra J, Braun K, Regli L. Combined bypass technique for contemporary revascularization of unilateral MCA and bilateral frontal territories in moyamoya vasculopathy. Acta Neurochir Suppl. 2014;119, in press.
87.
Muto J, Oi S. Intradural arteriosynangiosis in pediatric moyamoya disease: modified technique of encephalo-duro-arterio-synangiosis with reduced operative damage to already growing revascularization. Childs Nerv Syst. 2009;25:607–12.PubMedCrossRef
88.
Pandey P, Steinberg GK. Neurosurgical advances in the treatment of moyamoya disease. Stroke. 2011;42:3304–10.PubMedCrossRef
89.
Zhao WG, Luo Q, Jia JB, Yu JL. Cerebral hyperperfusion syndrome after revascularization surgery in patients with moyamoya disease. Br J Neurosurg. 2013;27:321–5.PubMedCrossRef
Metadata
Title
Recent Advances in Moyamoya Disease: Pathophysiology and Treatment
Authors
Annick Kronenburg
Kees P. J. Braun
Albert van der Zwan
Catharina J. M. Klijn
Publication date
01-01-2014
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 1/2014
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-013-0423-7

Other articles of this Issue 1/2014

Current Neurology and Neuroscience Reports 1/2014 Go to the issue

Epilepsy (C Bazil, Section Editor)

The Effects of Mozart’s Music on Interictal Activity in Epileptic Patients: Systematic Review and Meta-analysis of the Literature

Neuroophthalmology (A Kawasaki, Section Editor)

Ocular Myasthenia Gravis: Controversies and Updates

Stroke (H Adams, Section Editor)

Diagnosis and Treatment of Arterial Dissections

Stroke (H Adams, Section Editor)

Diagnosis and Treatment of Cerebral Venous and Sinus Thrombosis

Stroke (H Adams, Section Editor)

Vascular Cognitive Impairment and Post-Stroke Cognitive Deficits

Stroke (H Adams, Section Editor)

Arterial Ischemic Stroke in Children: Risk Factors and Etiologies